The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis

Infectious Disorders - Drug Targets

Volumn 11, Issue 5, 2011, Pages 504-513

  James, S H ^a   Prichard, M N ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Cidofovir; Cytomegalovirus; Foscarnet; Ganciclovir; Recombinant phenotyping; Resistance; Valganciclovir

Indexed keywords

AIC 246; ANTIVIRUS AGENT; ARTESUNATE; BENZIMIDAVIR; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CYCLOPROPAVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; LEFLUNOMIDE; PHOSPHOTRANSFERASE; UL97 KINASE; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; GENE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; NONHUMAN; PHENOTYPE; UL54 GENE; UL97 GENE; VIRAL GENETICS; VIRUS GENOME; VIRUS ISOLATION;

EID: 80054100036     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/187152611797636668     Document Type: Article

References (122)

1. Torres-Madriz, G.; Boucher, H.W. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin. Infect. Dis., 2008, 47 (5), 702-711.
2. Griffiths, P. D. Cytomegalovirus therapy: current constraints and future opportunities. Curr. Opin. Infect. Dis., 2001, 14 (6), 765-768.
3. Meyers, J.D.; Flournoy, N.; Thomas, E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect. Dis., 1986, 153 (3), 478-488.
4. Kedhar, S.R.; Jabs, D.A. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Herpes, 2007, 14 (3), 66-71.
5. Demmler, G.J. Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev. Infect. Dis., 1991, 13 (2), 315-329.
6. Morton, C.C.; Nance, W.E. Newborn hearing screening--a silent revolution. N. Engl. J. Med., 2006, 354 (20), 2151-2164.
7. Boppana, S.B.; Fowler, K.B.; Britt, W.J.; Stagno, S.; Pass, R.F. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics, 1999, 104 (1 pt. 1), 55-60.
8. Ross, S.A.; Fowler, K.B.; Ashrith, G.; Stagno, S.; Britt, W.J.; Pass, R.F.; Boppana, S.B. Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. J. Pediatr., 2006, 148 (3), 332-336.
9. James, S.H.; Kimberlin, D.W.; Whitley, R.J. Antiviral therapy for herpesvirus central nervous system infections: neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection. Antiviral Res., 2009, 83 (3), 207-213.
10. Nassetta, L.; Kimberlin, D.; Whitley, R. Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. J. Antimicrob. Chemother., 2009, 63 (5), 862-867.
11. Fowler, K.B.; McCollister, F.P.; Dahle, A.J.; Boppana, S.; Britt, W.J.; Pass, R.F. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J. Pediatr., 1997, 130 (4), 624-630.
12. Kimberlin, D.W.; Lin, C.Y.; Sánchez, P.J.; Demmler, G.J.; Dankner, W.; Shelton, M.; Jacobs, R.F.; Vaudry, W.; Pass, R.F.; Kiell, J.M.; Soong, S.J.; Whitley, R.J.; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr., 2003, 143 (1), 16-25.
13. Biron, K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res., 2006, 71 (2-3), 154-163.
14. Andrei, G.; De Clercq, E.; Snoeck, R. Drug targets in cytomegalovirus infection. Infect. Disord. Drug Targets, 2009, 9 (2), 201-222.
15. Jacobson, M.A. Current management of cytomegalovirus disease in patients with AIDS. AIDS Res. Hum. Retroviruses, 1994, 10 (8), 917-923.
16. Walmsley, S.L.; Chew, E.; Read, S.E.; Vellend, H.; Salit, I.; Rachlis, A.; Fanning, M.M. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet). J. Infect. Dis., 1988, 157 (3), 569-572.
17. Jacobson, M.A. Ganciclovir therapy for severe cytomegalovirus infection in immunocompetent patients. Clin. Infect. Dis., 1997, 25 (6), 1487-1488.
18. Jacobson, M.A. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med., 1997, 337 (2), 105-114. [Erratum in: N. Engl. J. Med., 1997, 337 (14), 1019].
19. Jabs, D.A.; Enger, C.; Dunn, J.P.; Forman, M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J. Infect. Dis., 1998, 177 (3), 770-773.
20. Limaye, A.P.; Corey, L.; Koelle, D.M.; Davis, C.L.; Boeckh, M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet, 2000, 356 (9230), 645-649.
21. Humar, A.; Lebranchu, Y.; Vincenti, F.; Blumberg, E.A.; Punch, J.D.; Limaye, A.P.; Abramowicz, D.; Jardine, A.G.; Voulgari, A.T.; Ives, J.; Hauser, I.A.; Peeters, P. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am. J. Transplant., 2010, 10 (5), 1228-1237.
22. Mocarski, E.S.; Liu, A.C.; Spaete, R.R. Structure and variability of the a sequence in the genome of human cytomegalovirus (Towne strain). J. Gen. Virol., 1987, 68 (pt. 8), 2223-2230.
23. Spaete, R.R.; Mocarski, E.S. The alpha sequence of the cytomegalovirus genome functions as a cleavage/packaging signal for herpes simplex virus defective genomes. J. Virol., 1985, 54 (3), 817-824.
24. Mocarski, E.S.; Roizman, B. Structure and role of the herpes simplex virus DNA termini in inversion, circularization and generation of virion DNA. Cell, 1982, 31 (1), 89-97.
25. Cha, T.A.; Tom, E.; Kemble, G.W.; Duke, G.M.; Mocarski, E.S.; Spaete, R.R. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol., 1996, 70 (1), 78-83.
26. Prichard, M.N.; Penfold, M.E.; Duke, G.M.; Spaete, R.R.; Kemble, G.W. A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev. Med. Virol., 2001, 11 (3), 191-200.
27. Dolan, A.; Cunningham, C.; Hector, R.D.; Hassan-Walker, A.F.; Lee, L.; Addison, C.; Dargan, D.J.; McGeoch, D.J.; Gatherer, D.; Emery, V.C.; Griffiths, P.D.; Sinzger, C.; McSharry, B.P.; Wilkinson, G.W.; Davison, A.J. Genetic content of wild-type human cytomegalovirus. J. Gen. Virol., 2004, 85 (pt. 5), 1301-1312.
28. Murphy, E.; Yu, D.; Grimwood, J.; Schmutz, J.; Dickson, M.; Jarvis, M.A.; Hahn, G.; Nelson, J.A.; Myers, R.M.; Shenk, T.E. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc. Natl. Acad. Sci. USA, 2003, 100 (25), 14976-14981.
29. Davison, A.J. Evolution of the herpesviruses. Vet. Microbiol., 2002, 86 (1-2), 69-88.
30. McGeoch, D.J.; Rixon, F.J.; Davison, A.J. Topics in herpesvirus genomics and evolution. Virus Res., 2006, 117 (1), 90-104.
31. Norberg, P.; Bergström, T.; Rekabdar, E.; Lindh, M.; Liljeqvist, J.A. Phylogenetic analysis of clinical herpes simplex virus type 1 isolates identified three genetic groups and recombinant viruses. J. Virol., 2004, 78 (19), 10755-10764.
32. Muir, W.B.; Nichols, R.; Breuer, J. Phylogenetic analysis of varicella-zoster virus: evidence of intercontinental spread of genotypes and recombination. J. Virol., 2002, 76 (4), 1971-1979.
33. Chou, S.W. Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors. J. Infect. Dis., 1989, 160 (1), 11-15.
34. Borgia, M.C.; Mandolini, C.; Barresi, C.; Battisti, G.; Carletti, F.; Capobianchi, M.R. Further evidence against the implication of active cytomegalovirus infection in vascular atherosclerotic diseases. Atherosclerosis, 2001, 157 (2), 457-462.
35. Huang, E.S.; Alford, C.A.; Reynolds, D.W.; Stagno, S.; Pass, R.F. Molecular epidemiology of cytomegalovirus infections in women and their infants. N. Engl. J. Med., 1980, 303 (17), 958-962.
36. Lurain, N.S.; Kapell, K.S.; Huang, D.D.; Short, J.A.; Paintsil, J.; Winkfield, E.; Benedict, C.A.; Ware, C.F.; Bremer, J.W. Human cytomegalovirus UL144 open reading frame: sequence hypervariability in low-passage clinical isolates. J. Virol., 1999, 73 (12), 10040-10050.
37. Chou, S. Molecular epidemiology of envelope glycoprotein H of human cytomegalovirus. J. Infect. Dis., 1992, 166 (3), 604-607.
38. Chou, S. Comparative analysis of sequence variation in gp116 and gp55 components of glycoprotein B of human cytomegalovirus. Virology, 1992, 188 (1), 388-390.
39. Chou, S.W.; Dennison, K.M. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization related epitopes. J. Infect. Dis., 1991, 163 (6), 1229-1234.
40. Murphy, E.; Rigoutsos, I.; Shibuya, T.; Shenk, T.E. Reevaluation of human cytomegalovirus coding potential. Proc. Natl. Acad. Sci. USA, 2003, 100 (23), 13585-13590.
41. Spaete, R.R.; Mocarski, E.S. Insertion and deletion mutagenesis of the human cytomegalovirus genome. Proc. Natl. Acad. Sci. USA, 1987, 84 (20), 7213-7217.
42. Hayashi, M.L.; Blankenship, C.; Shenk, T. Human cytomegalovirus UL69 protein is required for efficient accumulation of infected cells in the G1 phase of the cell cycle. Proc. Natl. Acad. Sci. USA, 2000, 97 (6), 2692-2696.
43. Prichard, M.N.; Gao, N.; Jairath, S.; Mulamba, G.; Krosky, P.; Coen, D.M.; Parker, B.O.; Pari, G.S. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol., 1999, 73 (7), 5663-5670.
44. Wagner, M.; Ruzsics, Z.; Koszinowski, U.H. Herpesvirus genetics has come of age. Trends Microbiol., 2002, 10 (7), 318-324.
45. Gill, R.B.; Frederick, S.L.; Hartline, C.B.; Chou, S.; Prichard, M.N. Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir. Virol. J., 2009, 6, 9.
46. Chou, S. Cytomegalovirus UL97 mutations in the era ofganciclovir and maribavir. Rev. Med. Virol., 2008, 18 (4), 233-246.
47. Faulds, D.; Heel, R.C. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs, 1990, 39 (4), 597-638.
48. Jung, D.; Dorr, A. Single-dose pharmacokinetics of valganciclovir in HIV-and CMV-seropositive subjects. J. Clin. Pharmacol., 1999, 39 (8), 800-804.
49. Sullivan, V.; Talarico, C.L.; Stanat, S.C.; Davis, M.; Coen, D.M.; Biron, K.K. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature, 1992, 358 (6382), 162-164. [Erratum in: Nature, 1992, 359 (6390), 85. Erratum in: Nature, 1993, 366 (6457), 756].
50. Biron, K.K.; Stanat, S.C.; Sorrell, J.B.; Fyfe, J.A.; Keller, P.M.; Lambe, C.U.; Nelson, D.J. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. USA, 1985, 82 (8), 2473-2477.
51. Cihlar, T.; Chen, M.S. Identification of enzymes catalyzing twostep phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol., 1996, 50 (6), 1502-1510.
52. Williams-Aziz, S.L.; Hartline, C.B.; Harden, E.A.; Daily, S.L.; Prichard, M.N.; Kushner, N.L.; Beadle, J.R.; Wan, W.B.; Hostetler, K.Y.; Kern, E.R. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob. Agents Chemother., 2005, 49 (9), 3724-3733.
53. Wagstaff, A.J.; Bryson, H.M. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs, 1994, 48 (2), 199-226.
54. Crumpacker, C.S. Mechanism of action of foscarnet against viral polymerases. Am. J. Med., 1992, 92 (2A), 3S-7S.
55. Gilbert, C.; Boivin, G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother., 2005, 49 (3), 873-883.
56. Erice, A. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev., 1999, 12 (2), 286-297.
57. Boivin, G.; Gilbert, C.; Gaudreau, A.; Greenfield, I.; Sudlow, R.; Roberts, N.A. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J. Infect. Dis., 2001, 184 (12), 1598-1602.
58. Chou, S.; Waldemer, R.H.; Senters, A.E.; Michels, K.S.; Kemble, G.W.; Miner, R.C.; Drew, W.L. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J. Infect. Dis., 2002, 185 (2), 162-169.
59. Lurain, N.S.; Chou, S. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev., 2010, 23 (4), 689-712.
60. Gilbert, C.; Bestman-Smith, J.; Boivin, G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat., 2002, 5 (2), 88-114.
61. Chou, S.; Miner, R.C.; Drew, W.L. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J. Infect. Dis., 2000, 182 (6), 1765-1768.
62. Scott, G.M.; Weinberg, A.; Rawlinson, W.D.; Chou, S. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob. Agents Chemother., 2007, 51 (1), 89-94.
63. Cihlar, T.; Fuller, M.D.; Cherrington, J.M. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol., 1998, 72 (7), 5927-5936.
64. Drew, W.L. Ganciclovir resistance: a matter of time and titre. Lancet, 2000, 356 (9230), 609-610.
65. Emery, V.C.; Griffiths, P.D. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc. Natl. Acad. Sci. USA, 2000, 97 (14), 8039-8044.
66. Limaye, A.P.; Raghu, G.; Koelle, D.M.; Ferrenberg, J.; Huang, M.L.; Boeckh, M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J. Infect. Dis., 2002, 185 (1), 20-27.
67. Zamora, M.R. Cytomegalovirus and lung transplantation. Am. J. Transplant., 2004, 498, 1219-1226.
68. Ahmed, J.; Velarde, C.; Ramos, M.; Ismail, K.; Serpa, J.; Ortigosa-Goggins, M.; Parasuraman, R.; Venkat, K.K. Outcome of low-dose ganciclovir for cytomegalovirus disease prophylaxis in renaltransplant recipients. Transplantation, 2004, 78 (11), 1689-1692.
69. Baldanti, F.; Sarasini, A.; Silini, E.; Barbi, M.; Lazzarin, A.; Biron, K.K.; Gerna, G. Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir-and foscarnetspecific resistance, respectively. Scand. J. Infect. Dis. Suppl., 1995, 99, 103-104.
70. Wolf, D.G.; Lee, D.J.; Spector, S.A. Detection of human cytomegalovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease. Antimicrob. Agents Chemother., 1995, 39 (11), 2552-2554.
71. Drew, W.L.; Miner, R.C.; Busch, D.F.; Follansbee, S.E.; Gullett, J.; Mehalko, S.G.; Gordon, S.M.; Owen, W.F., Jr.; Matthews, T.R.; Buhles, W.C.; DeArmond, B. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis., 1991, 163 (4), 716-719.
72. Martin, B.K.; Ricks, M.O.; Forman, M.S.; Jabs, D.A. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis. Clin. Infect. Dis., 2007, 44 (7), 1001-1008.
73. Kruger, R.M.; Shannon, W.D.; Arens, M.Q.; Lynch, J.P.; Storch, G.A.; Trulock, E.P. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation, 1999, 68 (9), 1272-1279.
74. Boivin, G.; Goyette, N.; Rollag, H.; Jardine, A.G.; Pescovitz, M.D.; Asberg, A.; Ives, J.; Hartmann, A.; Humar, A. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir. Ther., 2009, 14 (5), 697-704.
75. Bhorade, S.M.; Lurain, N.S.; Jordan, A.; Leischner, J.; Villanueva, J.; Durazo, R.; Creech, S.; Vigneswaran, W.T.; Garrity, E.R. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J. Heart Lung Transplant., 2002, 21 (12), 1274-1282.
76. Marfori, J.E.; Exner, M.M.; Marousek, G.I.; Chou, S.; Drew, W.L. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J. Clin. Virol., 2007, 38 (2), 120-125.
77. Nichols, W.G.; Corey, L.; Gooley, T.; Drew, W.L.; Miner, R.; Huang, M.; Davis, C.; Boeckh, M. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood, 2001, 97 (4), 867-874.
78. Gilbert, C.; Roy, J.; Belanger, R.; Delage, R.; Beliveau, C.; Demers, C.; Boivin, G. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob. Agents Chemother., 2001, 45 (12), 3669-3671.
79. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. Arch. Ophthalmol., 1996, 114 (1), 23-33.
80. West, P.; Schmiedeskamp, M.; Neeley, H.; Oberholzer, J.; Benedetti, E.; Kaplan, B. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. Transpl. Infect. Dis., 2008, 10 (2), 129-132.
81. Mylonakis, E.; Kallas, W.M.; Fishman, J.A. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solidorgan transplant recipients. Clin. Infect. Dis., 2002, 34 (10), 1337-1341.
82. Biron, K.K.; Harvey, R.J.; Chamberlain, S.C.; Good, S.S.; Smith, A.A., 3rd; Davis, M.G.; Talarico, C.L.; Miller, W.H.; Ferris, R.; Dornsife, R.E.; Stanat, S.C.; Drach, J.C.; Townsend, L.B.; Koszalka, G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole Lriboside with a unique mode of action. Antimicrob. Agents Chemother., 2002, 46 (8), 2365-2372.
83. Prichard, M.N. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev. Med. Virol., 2009, 19 (4), 215-229.
84. Beadle, J.R.; Hartline, C.; Aldern, K.A.; Rodriguez, N.; Harden, E.; Kern, E.R.; Hostetler, K.Y. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother., 2002, 46 (8), 2381-2386.
85. Bidanset, D.J.; Beadle, J.R.; Wan, W.B.; Hostetler, K.Y.; Kern, E.R. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J. Infect. Dis., 2004, 190 (3), 499-503.
86. Bidanset, D.J.; Rybak, R.J.; Hartline, C.B.; Kern, E.R. Efficacy of ganciclovir and cidofovir against human cytomegalovirus replication in SCID mice implanted with human retinal tissue. Antiviral Res., 2004, 63 (1), 61-64.
87. Ciesla, S.L.; Trahan, J.; Wan, W.B.; Beadle, J.R.; Aldern, K.A.; Painter, G.R.; Hostetler, K.Y. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res., 2003, 59 (3), 163-171.
88. Painter, G.R.; Trost, C.L.; Lampert, M.B.; Almond, R.M.; Buller, M.; Kern, E.; Painter, G.P.; Robertson, A.T.; Frazer, N.; O'Mahony, R. CMX001. Anti-smallpox agent, anti-cytomegalovirus agent, viral polymerase inhibitor. Drugs Fut., 2008, 33 (8), 655.
89. Lischka, P.; Hewlett, G.; Wunberg, T.; Baumeister, J.; Paulsen, D.; Goldner, T.; Ruebsamen-Schaeff, H.; Zimmermann, H. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob. Agents Chemother., 2010, 54 (3), 1290-1297.
90. Waldman, W.J.; Knight, D.A.; Blinder, L.; Shen, J.; Lurain, N.S.; Miller, D.M.; Sedmak, D.D.; Williams, J.W.; Chong, A.S. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology, 1999, 42 (5-6), 412-418.
91. Avery, R.K. Update in management of ganciclovir-resistant cytomegalovirus infection. Curr. Opin. Infect. Dis., 2008, 21 (4), 433-437.
92. Kaptein, S.J.; Efferth, T.; Leis, M.; Rechter, S.; Auerochs, S.; Kalmer, M.; Bruggeman, C.A.; Vink, C.; Stamminger, T.; Marschall, M. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res., 2006, 69 (2), 60-69.
93. Shapira, M.Y.; Resnick, I.B.; Chou, S.; Neumann, A.U.; Lurain, N.S.; Stamminger, T.; Caplan, O.; Saleh, N.; Efferth, T.; Marschall, M.; Wolf, D.G. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin. Infect. Dis., 2008, 46 (9), 1455-1457.
94. Kern, E.R.; Kushner, N.L.; Hartline, C.B.; Williams-Aziz, S.L.; Harden, E.A.; Zhou, S.; Zemlicka, J.; Prichard, M.N. In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob. Agents Chemother., 2005, 49 (3), 1039-1045.
95. Kern, E.R.; Bidanset, D.J.; Hartline, C.B.; Yan, Z.; Zemlicka, J.; Quenelle, D.C. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob. Agents Chemother., 2004, 48 (12), 4745-4753.
96. Kern, E.R.; Hartline, C.B.; Rybak, R.J.; Drach, J.C.; Townsend, L.B.; Biron, K.K.; Bidanset, D.J. Activities of benzimidazole Dand L-ribonucleosides in animal models of cytomegalovirus infections. Antimicrob. Agents Chemother., 2004, 48 (5), 1749-1755.
97. Hamprecht, K.; Eckle, T.; Prix, L.; Faul, C.; Einsele, H.; Jahn, G. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J. Infect. Dis., 2003, 187 (1), 139-143.
98. Gilbert, C.; Boivin, G. Discordant phenotypes and genotypes of cytomegalovirus (CMV) in patients with AIDS and relapsing CMV retinitis. AIDS, 2003, 17 (3), 337-341.
99. Landry, M.L.; Stanat, S.; Biron, K.; Brambilla, D.; Britt, W.; Jokela, J.; Chou, S.; Drew, W.L.; Erice, A.; Gilliam, B.; Lurain, N.; Manischewitz, J.; Miner, R.; Nokta, M.; Reichelderfer, P.; Spector, S.; Weinberg, A.; Yen-Lieberman, B.; Crumpacker, C. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob. Agents Chemother., 2000, 44 (3), 688-692.
100. Chevillotte, M.; von Einem, J.; Meier, B.M.; Lin, F.M.; Kestler, H.A.; Mertens, T. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Res., 2010, 85 (2), 318-327.
101. Schnepf, N.; Boiteau, N.; Petit, F.; Alain, S.; Sanson-Le Pors, M.J.; Mazeron, M.C. Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR. Antiviral Res., 2009, 81 (1), 64-67.
102. Drew, W.L.; Miner, R.; Saleh, E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin. Diagn. Virol., 1993, 1 (3), 179-185.
103. Chou, S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob. Agents Chemother., 2010, 54 (6), 2371-2378.
104. Chou, S.; Lurain, N.S.; Thompson, K.D.; Miner, R.C.; Drew, W.L. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis., 2003, 188 (1), 32-39.
105. Chou, S.; Erice, A.; Jordan, M.C.; Vercellotti, G.M.; Michels, K.R.; Talarico, C.L.; Stanat, S.C.; Biron, K.K. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis., 1995, 171 (3), 576-583.
106. Hanson, M.N.; Preheim, L.C.; Chou, S.; Talarico, C.L.; Biron, K.K.; Erice, A. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob. Agents Chemother., 1995, 39 (5), 1204-1205.
107. Prix, L.; Hamprecht, K.; Holzhüter, B.; Handgretinger, R.; Klingebiel, T.; Jahn, G. Comprehensive restriction analysis of the UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child. J. Infect. Dis., 1999, 180 (2), 491-495.
108. Eriksson, N.; Pachter, L.; Mitsuya, Y.; Rhee, S.Y.; Wang, C.; Gharizadeh, B.; Ronaghi, M.; Shafer, R.W.; Beerenwinkel, N. Viral population estimation using pyrosequencing. PLoS Comput Biol., 2008, 4 (4), e1000074.
109. Ronaghi, M.; Karamohamed, S.; Pettersson, B.; Uhlén, M.; Nyrén, P. Real-time DNA sequencing using detection of pyrophosphate release. Anal. Biochem., 1996, 242 (1), 84-89.
110. Ronaghi, M.; Uhlén, M.; Nyrén, P. A sequencing method based on real-time pyrophosphate. Science, 1998, 281 (5375), 363-365.
111. Eckle, T.; Prix, L.; Jahn, G.; Klingebiel, T.; Handgretinger, R.; Selle, B.; Hamprecht, K. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood, 2000, 96 (9), 3286-3289.
112. Chou, S.; Lurain, N.S.; Weinberg, A.; Cai, G.Y.; Sharma, P.L.; Crumpacker, C.S. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. Antimicrob. Agents Chemother., 1999, 43 (6), 1500-1502.
113. Martin, M.; Gilbert, C.; Covington, E.; Boivin, G. Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. J. Infect. Dis., 2006, 194 (5), 579-583.
114. Lurain, N.S.; Thompson, K.D.; Holmes, E.W.; Read, G.S. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J. Virol., 1992, 66 (12), 7146-7152.
115. Baldanti, F.; Silini, E.; Sarasini, A.; Talarico, C.L.; Stanat, S.C.; Biron, K.K.; Furione, M.; Bono, F.; Palù, G.; Gerna, G. A threenucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J. Virol., 1995, 69 (2), 796-800.
116. Borst, E.M.; Hahn, G.; Koszinowski, U.H.; Messerle, M. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol., 1999, 73 (10), 8320-8329.
117. Prichard, M.N.; Sztul, E.; Daily, S.L.; Perry, A.L.; Frederick, S.L.; Gill, R.B.; Hartline, C.B.; Streblow, D.N.; Varnum, S.M.; Smith, R.D.; Kern, E.R. Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J. Virol., 2008, 82 (10), 5054-5067.
118. Chou, S. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob. Agents Chemother., 2009, 53 (1), 81-85.
119. Chevillotte, M.; Schubert, A.; Mertens, T.; von Einem, J. Fluorescence-based assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness. Antimicrob. Agents Chemother., 2009, 53 (9), 3752-3761.
120. Warming, S.; Costantino, N.; Court, D.L.; Jenkins, N.A.; Copeland, N.G. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res., 2005, 33 (4), e36.
121. Tischer, B.K.; von Einem, J.; Kaufer, B.; Osterrieder, N. Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques, 2006, 40 (2), 191-197.
122. Wang, S.; Zhao, Y.; Leiby, M.; Zhu, J. A new positive/negative selection scheme for precise BAC recombineering. Mol. Biotechnol., 2009, 42 (1), 110-116.